Loading...
Loading...
Analysts at Credit Suisse downgraded
Gilead Sciences Inc. GILD from Outperform to Neutral.
The price target for Gilead Sciences has been lowered from $130 to $115.
Gilead Sciences shares have surged 26.86% over the past 52 weeks, while the S&P 500 index has gained 14.77% in the same period.
Gilead Sciences' shares fell 1.15% to $98.75 in pre-market trading.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in